Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-30), DanCann Pharma AS's 3-1 Month Momentum % is N/A%.
The industry rank for DanCann Pharma AS's 3-1 Month Momentum % or its related term are showing as below:
DCPXF's 3-1 Month Momentum % is not ranked *
in the Drug Manufacturers industry.
Industry Median: -8.255 * Ranked among companies with meaningful 3-1 Month Momentum % only.
DanCann Pharma AS (GREY:DCPXF) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
DanCann Pharma AS 3-1 Month Momentum % Related Terms
DCPXF vs ZTS, UTHR, RGC: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, DanCann Pharma AS's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DanCann Pharma AS 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DanCann Pharma AS's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where DanCann Pharma AS's 3-1 Month Momentum % falls into.
DanCann Pharma AS (GREY:DCPXF) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DanCann Pharma AS (DCPXF) has a 3-1 Month Momentum % of N/A% as of Jul. 30, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on DanCann Pharma AS and its competitors.
Is DanCann Pharma AS's 3-1 Month Momentum % too high?
DanCann Pharma AS's current 3-1 Month Momentum % is N/A%. Overall, DanCann Pharma AS has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does DanCann Pharma AS's 3-1 Month Momentum % compare to ZTS and UTHR?
DanCann Pharma AS's 3-1 Month Momentum % of N/A% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on DanCann Pharma AS and its competitors. DanCann Pharma AS's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DanCann Pharma AS stock overvalued right now?
DanCann Pharma AS (DCPXF) has a current 3-1 Month Momentum % of N/A%. The stock's GF Value™ is $37.14, compared to a current price of $10.00 — trading 73.1% below its estimated fair value. The current 3-1 Month Momentum % is N/A%. DanCann Pharma AS's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For DanCann Pharma AS (DCPXF), the current 3-1 Month Momentum % is N/A% as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DanCann Pharma AS (DCPXF) Overvalued in 2026?
Based on GuruFocus' analysis, DanCann Pharma AS stock appears to be undervalued.
The current stock price of $10.00 is trading 73.1% below its estimated GF Value™ of $37.14.
Key valuation signals for DCPXF:
3-1 Month Momentum %: N/A%
GF Value™: $37.14 vs. price of $10.00 (73.1% below fair value)
No single metric tells the full story. See the DCPXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DanCann Pharma AS is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company. The company is focused on discovering, developing, manufacturing, and commercializing novel cannabinoid therapeutics for a broad range of diseases.
20GF Score
Get the complete analysis for DCPXF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DCPXF has been successfully added to your 
